Vaccinex Appoints Valerie Iddison, M.D. as Chief Medical Officer

Rochester, NY May 28, 2013 – Vaccinex announced today that Dr. Valerie Iddison has joined the company as Chief Medical Officer and a member of the Company’s Executive Team. Dr. Iddison will provide medical guidance, strategic leadership and oversight of Vaccinex’s clinical development programs, including selection of target indications, protocol design and design of clinical monitoring end-points.

Maurice Zauderer. Ph.D., Vaccinex CEO commented: “The appointment of Dr. Iddison as Chief Medical Officer comes at an exciting time when Vaccinex is engaged in two promising clinical trials of patients with certain types of cancer or with multiple sclerosis and anticipates additional trials in these and other indications in the future. The Company is delighted that Dr. Iddison has accepted this leadership position. Her extensive experience in clinical development and, in particular, in immunotherapy of cancer will be a great asset in our continuing efforts to develop new products to address unmet needs.”

Dr. Iddison received her medical degree from the University of Nantes in France and has extensive experience in clinical development and product launch in the fields of immuno-oncology and infectious disease. After several years at the French pharmaceutical company, Ipsen, and at Amgen, France, Dr. Iddison served in the position of European Medical Director, Oncology Clinical Development at GlaxoSmithKline in the United Kingdom. Since 2008 she has been a member of the Executive team at Bristol-Myers Squibb (BMS), most recently in the position of Executive Director, Global Medical Affairs, Oncology. In her capacity as Head of Global Medical Affairs for the Immuno-Oncology portfolio at BMS, Dr. Iddison was responsible for key products in the BMS pipeline.

About Vaccinex, Inc.

Founded in 1997 and located in Rochester, NY, Vaccinex, Inc. is a privately held clinical-stage biotechnology company engaged in the discovery and development of human therapeutic monoclonal antibodies and vaccines to treat serious diseases with unmet needs, including cancer, multiple sclerosis, and other autoimmune diseases.